Gefitinib (250mg)b . . . . . . .. . ..

GEFISTERIS 250
Gefitinib (250mg)

Gefisteris 250 is an oncology medication used in the treatment of certain cancers. It contains Gefitinib as the active ingredient, a targeted therapy drug that belongs to the class of epidermal growth factor receptor (EGFR) inhibitors. Gefitinib works by interfering with the action of a protein that is involved in the growth of cancer cells, specifically targeting the EGFR pathway. It is primarily used to treat non-small cell lung cancer (NSCLC), particularly in patients who have certain mutations in the EGFR gene.

This article provides an in-depth look at Gefisteris 250, including its benefits, key features, ingredients, usage guidelines, potential side effects, and frequently asked questions (FAQs).

Benefits

1. Targeted Cancer Treatment

Gefisteris 250 contains Gefitinib, which selectively inhibits the EGFR protein that plays a crucial role in the growth and spread of cancer cells. This makes it a targeted therapy option, meaning it directly targets cancer cells while sparing most healthy cells, reducing overall toxicity compared to traditional chemotherapy.

2. Effective for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)

Gefitinib has been proven to be highly effective in treating EGFR-positive NSCLC. It is often used in patients whose cancer has a specific mutation in the EGFR gene. In these patients, Gefitinib blocks the signaling pathways that promote cancer cell growth, leading to improved outcomes and prolonged survival.

3. Oral Administration for Convenience

Gefisteris 250 is an oral medication, offering a more convenient treatment option compared to intravenous therapies. This allows patients to take the medication at home, leading to less frequent hospital visits and a better overall quality of life during treatment.

4. Fewer Side Effects than Traditional Chemotherapy

Since Gefitinib targets the specific mechanisms that drive cancer cell growth, it generally causes fewer and less severe side effects compared to traditional chemotherapy. This means that patients undergoing treatment with Gefisteris 250 may experience less nausea, vomiting, and hair loss.

5. Potential to Improve Survival Rates

For patients with EGFR-positive metastatic NSCLC, Gefitinib has been shown to improve progression-free survival. It can shrink tumors and slow the growth of cancer, potentially extending life expectancy.

Key Features and Ingredients

Key Features:

• Targeted Therapy: Gefisteris 250 targets the EGFR pathway, which is responsible for tumor growth in certain cancers. This selective inhibition helps to minimize damage to healthy cells.
• Oral Administration: Gefisteris 250 is taken in pill form, which is more convenient for patients compared to intravenous treatments.
• Effective for EGFR Mutated Cancers: The drug is particularly effective for patients with EGFR mutations, specifically in non-small cell lung cancer (NSCLC).
• Well-Tolerated: Compared to traditional chemotherapy, Gefisteris 250 tends to have a more manageable side-effect profile, with fewer systemic issues.
• Used for Advanced Cancers: Gefisteris 250 is used in advanced-stage cancer, particularly in cases of metastatic lung cancer.

Ingredients:

• Active Ingredient – Gefitinib: The main ingredient in Gefisteris 250 is Gefitinib, which works by binding to the EGFR receptor on the surface of cancer cells. By inhibiting EGFR signaling, Gefitinib helps to prevent the cancer cells from growing and dividing.

• Excipients (Inactive Ingredients): In addition to Gefitinib, the medication contains various excipients that help to form the tablet. These can include stabilizers, binders, and fillers that ensure the tablet remains effective and safe for consumption.

Usage Guidelines

Gefisteris 250 should be taken exactly as prescribed by the oncologist. The recommended dosage and usage instructions may vary depending on the patient's condition, the type of cancer being treated, and how the patient responds to the medication.

Dosage and Administration:

• Usual Dose: The typical dose for adults is 250 mg once daily. It should be taken at the same time each day for consistent therapeutic effect.
• Swallowing the Tablet: The tablet should be swallowed whole with water. It should not be chewed, crushed, or broken.
• With or Without Food: Gefisteris 250 can be taken with or without food. However, if you experience stomach upset, taking it with food may help reduce discomfort.
• Missed Dose: If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not take two doses to make up for a missed dose.

Monitoring During Treatment:

Patients taking Gefisteris 250 should be closely monitored for side effects, especially liver function tests and eye exams. Regular check-ups are necessary to ensure the medication is working effectively and to detect any potential complications.

Potential Side Effects

While Gefisteris 250 is generally well-tolerated, like all medications, it can cause side effects. Most side effects are manageable and can be addressed with dose adjustments or supportive care.

Common Side Effects:

• Skin Reactions: Rash, acne-like eruptions, and dry skin are common. These are usually mild but may require treatment to manage symptoms.
• Diarrhea: Gefitinib can cause diarrhea, which may be severe in some cases. It is important to monitor bowel movements and report persistent diarrhea to a healthcare provider.
• Liver Toxicity: Gefitinib can cause liver problems, so liver function tests are important to monitor during treatment. Symptoms of liver issues include jaundice (yellowing of the skin or eyes), dark urine, or persistent abdominal pain.
• Fatigue: Some patients may feel tired or weak during treatment, especially early on in the therapy.
• Loss of Appetite and Weight Loss: Decreased appetite and unintended weight loss are possible side effects.

Serious Side Effects:

• Interstitial Lung Disease (ILD): In rare cases, Gefitinib can cause lung problems, including inflammation and scarring of lung tissue. Symptoms include difficulty breathing, persistent cough, or fever. If these symptoms occur, it is crucial to seek medical attention immediately.
• Severe Allergic Reactions: Anaphylaxis, rash, swelling of the face or throat, or difficulty breathing are severe allergic reactions that require immediate medical attention.

FAQ Section

1. What is Gefisteris 250 used for?

Gefisteris 250 is used for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations. It is a targeted therapy that blocks the EGFR protein, which plays a key role in cancer cell growth.

2. How does Gefisteris 250 work?

Gefisteris 250 contains Gefitinib, which inhibits the EGFR pathway, a signaling pathway involved in cancer cell proliferation. By blocking this pathway, Gefitinib prevents cancer cells from growing and dividing.

3. How should I take Gefisteris 250?

Gefisteris 250 should be taken orally, once daily, at the same time each day. The tablet should be swallowed whole with a glass of water and can be taken with or without food.

4. What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not take two doses to make up for a missed dose.

5. What are the common side effects of Gefisteris 250?

Common side effects include skin reactions (rash), diarrhea, liver toxicity, fatigue, and loss of appetite. These side effects are usually mild and can be managed with proper care.

6. Can Gefisteris 250 be used in combination with other treatments?

Yes, Gefisteris 250 can be used in combination with other therapies, especially in the treatment of metastatic EGFR-positive lung cancer. The combination approach depends on the oncologist’s assessment and the specific type of cancer.

7. How long will I need to take Gefisteris 250?

The duration of treatment depends on your response to the medication and the stage of your cancer. Your oncologist will determine the treatment length and may adjust your dosage based on your progress and side effects.

Conclusion

Gefisteris 250 is a targeted therapy that offers an effective treatment option for EGFR-positive non-small cell lung cancer (NSCLC). By targeting the EGFR pathway, it helps to block the signals that promote cancer cell growth, leading to improved survival rates and potentially fewer side effects compared to traditional chemotherapy. 

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW